FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Among patients with metastatic pancreatic cancer, combination chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) leads to longer overall survival than gemcitabine therapy. We compared the efficacy and safety of a modified FOLFIRINOX regimen with gemcitabine as adjuvant therapy in patients with resected pancreatic cancer. METHODS: We randomly assigned 493 patients with resected pancreatic ductal adenocarcinoma to receive a modified FOLFIRINOX regimen (oxaliplatin [85 mg per square meter of body-surface area], irinotecan [180 mg per square meter, reduced to 150 mg per square meter after a protocol-specified safety analysis], leucovorin [400 mg per square meter], and fluorouracil [2400 mg per square meter] every 2 weeks) or gemcitabine (1000 mg per square meter on days 1, 8, and 15 every 4 weeks) for 24 weeks. The primary end point was disease-free survival. Secondary end points included overall survival and safety. RESULTS: At a median follow-up of 33.6 months, the median disease-free survival was 21.6 months in the modified-FOLFIRINOX group and 12.8 months in the gemcitabine group (stratified hazard ratio for cancer-related event, second cancer, or death, 0.58; 95% confidence interval [CI], 0.46 to 0.73; P<0.001). The disease-free survival rate at 3 years was 39.7% in the modified-FOLFIRINOX group and 21.4% in the gemcitabine group. The median overall survival was 54.4 months in the modified-FOLFIRINOX group and 35.0 months in the gemcitabine group (stratified hazard ratio for death, 0.64; 95% CI, 0.48 to 0.86; P=0.003). The overall survival rate at 3 years was 63.4% in the modified-FOLFIRINOX group and 48.6% in the gemcitabine group. Adverse events of grade 3 or 4 occurred in 75.9% of the patients in the modified-FOLFIRINOX group and in 52.9% of those in the gemcitabine group. One patient in the gemcitabine group died from toxic effects (interstitial pneumonitis). CONCLUSIONS: Adjuvant therapy with a modified FOLFIRINOX regimen led to significantly longer survival than gemcitabine among patients with resected pancreatic cancer, at the expense of a higher incidence of toxic effects. (Funded by R&D Unicancer and others; ClinicalTrials.gov number, NCT01526135 ; EudraCT number, 2011-002026-52 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Polychemotherapy, either with 5-fluorouracil (5-FU), irinotecan and oxaliplatin in combination with folinic acid (FOLFIRINOX), or with gemcitabine and nab-paclitaxel (GnP), is considered the standard of care for patients suffering from metastatic PDAC (mPDAC)3,4.”
From Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer (2023) · cites this paper as [4]
In the citing paper
“Less than half of all patients respond to the primary treatment for PDAC, chemotherapy3,4”
From Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer (2023) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Siegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,579
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Self-citationRahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
TNM Classification of Malignant Tumors
Carter, D. (1998) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199810000-00016 · Cited by 6,330
Proportional hazards tests and diagnostics based on weighted residuals
GRAMBSCH, P. M., & THERNEAU, T. M. (1994) · Biometrika · doi:10.1093/biomet/81.3.515 · Cited by 5,885
A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer
Neoptolemos, J. P., Stocken, D. D., Friess, H., Bassi, C., Dunn, J. A., Hickey, H., Beger, H., Fernandez-Cruz, L., Dervenis, C., Lacaine, F., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032295 · Cited by 2,716
Oettle, H., Post, S., Neuhaus, P., Gellert, K., Langrehr, J., Ridwelski, K., Schramm, H., Fahlke, J., Zuelke, C., Burkart, C., et al. (2007) · JAMA · doi:10.1001/jama.297.3.267 · Cited by 2,419
Neoptolemos, J. P., Palmer, D. H., Ghaneh, P., Psarelli, E. E., Valle, J. W., Halloran, C. M., Faluyi, O., O'Reilly, D. A., Cunningham, D., Wadsley, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32409-6 · Cited by 1,926
Self-citationOettle, H., Neuhaus, P., Hochhaus, A., Hartmann, J. T., Gellert, K., Ridwelski, K., Niedergethmann, M., Zülke, C., Fahlke, J., Arning, M. B., et al. (2013) · JAMA · doi:10.1001/jama.2013.279201 · Cited by 1,794
Research works printed but not linked: 1
- Early Breast Cancer Trialists’ Collaborative Group. Treatment of early breast cancer. Vol. 1. Worldwide evidence 1985–1990. Oxford England: Oxford University Press 1990.
Cited by
Items 401–500 of 1,002
Targeting hedgehog signaling in pancreatic ductal adenocarcinoma
Quatannens, D., Verhoeven, Y., van Dam, P. A., Lardon, F., Prenen, H., Roeyen, G., Peeters, M., Smits, E., & Audenaerde, J. R. M. V. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108107 · Cited by 40
Lee, W., Song, G., & Bae, H. (2022) · Marine Drugs · doi:10.3390/md20080473 · Cited by 40
“a number of side effects associated with FOLFIRINOX have been reported, including diarrhea, neurotoxicity, fatigue, and myelosuppression [7,8].”
BackgroundOkuno, K., Xu, C., Pascual-Sabater, S., Tokunaga, M., Han, H., Fillat, C., Kinugasa, Y., & Goel, A. (2022) · Pharmaceuticals · doi:10.3390/ph15101199 · Cited by 40
Stereotactic ablative radiation for pancreatic cancer on a 1.5 Telsa magnetic resonance-linac system
Tringale, K. R., Tyagi, N., Reyngold, M., Romesser, P. B., Wu, A. J.-C., O'Reilly, E. M., Varghese, A. M., Scripes, P. G., Khalil, D. N., Park, W., et al. (2022) · Physics and Imaging in Radiation Oncology · doi:10.1016/j.phro.2022.10.003 · Cited by 39
“Improvements in systemic therapies seem to have modestly improved survival outcomes [4]; however, studies often include patients who were able to have surgery and median survival results have improved as the proportion of resected patients increases [5,6].”
BackgroundPancreatic cancer and exosomes: role in progression, diagnosis, monitoring, and treatment
Fang, X., Lan, H., Jin, K., & Qian, J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1149551 · Cited by 39
Conversion Surgery for Advanced Pancreatic Cancer
Hank, T. P., & Strobel, O. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8111945 · Cited by 37
Basiliya, K., Veldhuijzen, G., Gerges, C., Maubach, J., Will, U., Elmunzer, B. J., Stommel, M. W. J., Akkermans, R., Siersema, P. D., & van Geenen, E.-J. M. (2020) · Endoscopy · doi:10.1055/a-1200-0199 · Cited by 35
“While the number of patients with a symptomatic PJS stenosis is limited, we expect that this number will increase as post-pancreaticoduodenectomy survival increases in the future with application of neoadjuvant strategies in periampullary cancer [23, 24].”
BackgroundCrippa, S., Giannone, F., Lena, M. S., Belfiori, G., Partelli, S., Tamburrino, D., Delpini, R., Pagnanelli, M., Pecorelli, N., Balzano, G., et al. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-020-09467-6 · Cited by 35
Recent advances in precision medicine for pancreatic ductal adenocarcinoma
Hayashi, H., Higashi, T., Miyata, T., Yamashita, Y., & Baba, H. (2021) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12436 · Cited by 39
The role of autophagy in pancreatic cancer progression
Wang, Y., Qin, C., Yang, G., Zhao, B., & Wang, W. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188592 · Cited by 36
Fonseca, A. L., Cherla, D. V., Kothari, A. N., Tzeng, C.-W. D., Heslin, M. J., Mehari, K. R., Johnston, F. M., & Cao, H. S. T. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-10709-4 · Cited by 35
Kong, Y., Dai, Y., Qi, D., Du, W., Ni, H., Zhang, F., Zhao, H., Shen, Q., Li, M., & Fan, Q. (2021) · ACS Applied Bio Materials · doi:10.1021/acsabm.1c00864 · Cited by 37
The Role of Toll-like Receptors (TLRs) Mediated Inflammation in Pancreatic Cancer Pathophysiology
Orlacchio, A., & Mazzone, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312743 · Cited by 36
“However, due to its toxicity, this therapeutic regime is not suitable for all patients making gemcitabine the standard drug used in the PC treatment [6].”
BackgroundResultYchou, M., Rivoire, M. L., Thézenas, S., Guimbaud, R., Ghiringhelli, F., Mercier-Blas, A., Mineur, L., François, É., Khemissa, F., Chauvenet, M., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-021-01644-y · Cited by 37
Self-citationTargeting KRAS in PDAC: A New Way to Cure It?
He, Q., Liu, Z., & Wang, J. (2022) · Cancers · doi:10.3390/cancers14204982 · Cited by 45
“6 months), making it a reliable adjunct treatment for patients with PDAC after tumor resection [36].”
BackgroundZhang, D., Lindstrom, A. R., Kim, E. J.-H., Hwang, C., Hall, M. L., Lin, T., & Li, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.890154 · Cited by 39
“Despite advances in targeted therapies for many other cancers, the only option for treating the majority of pancreatic cancers remains chemotherapy (2).”
BackgroundKang, Y., Deng, J., Ling, J., Li, X., Chiang, Y., Koay, E. J., Wang, H., Burks, J. K., Chiao, P. J., Hurd, M. W., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci151604 · Cited by 38
Woeste, M. R., Shrestha, R., Geller, A. E., Li, S., Montoya-Durango, D. E., Ding, C., Hu, X., Li, H., Puckett, A. H., Mitchell, R. A., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006221 · Cited by 36
“6 Therefore, a critical need exists to develop and offer more efficacious treatment options within the setting of PC. Immune checkpoint inhibitor (ICI) therapy has undoubtedly transformed many solid cancer treatment algorithms, however, the promises of ICI have failed to be translated to PC. 7 This…”
He, C., Wang, J., Sun, S., Zhang, Y., Lin, X., Lao, X., Cui, B., & Li, S. (2019) · BMC Cancer · doi:10.1186/s12885-019-5607-3 · Cited by 37
Defining Value for Pancreatic Surgery in Early-Stage Pancreatic Cancer
Bateni, S. B., Gingrich, A. A., Hoch, J. S., Canter, R. J., & Bold, R. J. (2019) · JAMA Surgery · doi:10.1001/jamasurg.2019.3019 · Cited by 35
Silvestris, N., Brunetti, O., Bittoni, A., Cataldo, I., Corsi, D. C., Crippa, S., D’Onofrio, M., Fiore, M., Giommoni, E., Milella, M., et al. (2020) · Cancers · doi:10.3390/cancers12061681 · Cited by 34
“…chemotherapy treatment with mFOLFIRINOX for 6 months should be considered as the first option over to gemcitabine monotherapy Strong positive [30] Low In patients with resectable disease, perioperative treatment with PEXG could improve surgical and oncological outcomes Weakly positive…”
BackgroundFOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma
Yoo, C., Hwang, I., Song, T. J., Lee, S. S., Jeong, J. H., Park, D. H., Seo, D. W., Lee, S. K., Kim, M., Byun, J. H., et al. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920953294 · Cited by 34
Moore, J. V., Tom, S., Scoggins, C. R., Philips, P., Egger, M. E., & Martin, R. C. G. (2021) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-020-04883-1 · Cited by 34
Inoue, Y., Oba, A., Ono, Y., Sato, T., Ito, H., & Takahashi, Y. (2021) · Cancers · doi:10.3390/cancers13081818 · Cited by 34
Wang, L. L., Scott, F. I., Boursi, B., Reiss, K. A., Williams, S. V., Glick, H. A., & Yang, Y. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.10.037 · Cited by 37
Kuang, W., Wang, X., Ding, J., Li, J., Ji, M., Chen, W., Wang, L., & Yang, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.805311 · Cited by 34
Felsenstein, M., Lindhammer, F., Feist, M., Hillebrandt, K. H., Timmermann, L., Benzing, C., Globke, B., Zocholl, D., Hu, M., Fehrenbach, U., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11092367 · Cited by 38
Pancreatic cancer – the past, the present, and the future
Andersson, R. E., Haglund, C., Seppänen, H. E., & Ansari, D. (2022) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2022.2067786 · Cited by 41
“0months among the gemcitabine group [70].”
Clinical Strategies Targeting the Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma
Skorupan, N., Domínguez, M. P., Ricci, S. L., & Alewine, C. (2022) · Cancers · doi:10.3390/cancers14174209 · Cited by 38
“The novel regimen will be given following neoadjuvant mFOLFIRINOX and radiation, and its effect on the TME will be assessed in surgical specimens.”
BackgroundInfluentialThe Role of Nrf2 in the Regulation of Mitochondrial Function and Ferroptosis in Pancreatic Cancer
Baiskhanova, D. M., & Schäfer, H. (2024) · Antioxidants · doi:10.3390/antiox13060696 · Cited by 44
“…as autophagy, altered metabolism of lipids, amino acids, as well as changes in the tumor microenvironment [104,105]. iron-dependent ROS aggregation, there are other causes of ferroptosis induction autophagy, altered metabolism of lipids, amino acids, as well as changes microenvironment [104,105].”
Unveiling the resistance to therapies in pancreatic ductal adenocarcinoma
Shah, A., Ganguly, K., Rauth, S., Sheree, S. S., Khan, I., Ganti, A. K., Ponnusamy, M. P., Kumar, S., Jain, M., & Batra, S. K. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101146 · Cited by 40
Adjuvant and neoadjuvant therapy for pancreatic cancer
Maeda, S., Unno, M., & Yu, J. (2019) · Journal of Pancreatology · doi:10.1097/jp9.0000000000000028 · Cited by 33
Smith, S. J., Li, C. M., Lingeman, R. G., Hickey, R. J., Liu, Y., Malkas, L. H., & Raoof, M. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.03.025 · Cited by 33
Navez, J., Bouchart, C., Lorenzo, D., Bali, M. A., Closset, J., & Laethem, J. V. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-020-09568-2 · Cited by 33
Favorable tumor biology in locally advanced pancreatic cancer—beyond CA19-9
Kinny‐Köster, B., Habib, J. R., Wolfgang, C. L., He, J. P., & Javed, A. A. (2021) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-20-426 · Cited by 35
“With the introduction of multi-agent chemotherapies such as FOLFIRINOX, it became possible to more effectively treat this cohort of patients (4,5).”
BackgroundAblation in Pancreatic Cancer: Past, Present and Future
Narayanan, G., Daye, D., Wilson, N. M., Noman, R., Mahendra, A. M., & Doshi, M. (2021) · Cancers · doi:10.3390/cancers13112511 · Cited by 35
“The combination therapy group had increased disease-free survival of 21.6 months vs. 12.8 months and improved median overall survival of 54.4 months vs. 35 months [10].”
InfluentialThe role of FOLFIRINOX in metastatic pancreatic cancer: a meta-analysis
Zhang, B., Zhou, F., Hong, J., Ng, D. M., Yang, T., Zhou, X., Jin, J., Zhou, F., Chen, P., & Xu, Y. (2021) · World Journal of Surgical Oncology · doi:10.1186/s12957-021-02291-6 · Cited by 36
“For the regimen of FOLFIRINOX, given the relatively large toxicity of FOLFIRINOX reported in previous studies and the higher physical requirements of this program [44], the population’s clinical application is not extensive and needs careful consideration.”
BackgroundThe Microbiome as a Potential Target for Therapeutic Manipulation in Pancreatic Cancer
Rahman, R. A., Lamarca, Á., Hubner, R. A., Valle, J. W., & McNamara, M. G. (2021) · Cancers · doi:10.3390/cancers13153779 · Cited by 36
Kobayashi, S., Koizume, S., Takahashi, T., Ueno, M., Oishi, R., Nagashima, S., Sano, Y., Fukushima, T., Tezuka, S., Morimoto, M., et al. (2021) · Cancer Science · doi:10.1111/cas.15106 · Cited by 33
“540 Disease status 184 (100) 13 (100) Resectable 6 (3) 0 (0) .”
Bachir, E. H., Poiraud, C., Paget, S., Stoup, N., Moghrabi, S. E., Duchêne, B., Jouy, N., Bongiovanni, A., Tardivel, M., Weiswald, L., et al. (2021) · Biology of the Cell · doi:10.1111/boc.202100003 · Cited by 38
Value of Neoadjuvant Radiation Therapy in the Management of Pancreatic Adenocarcinoma
Hall, W. A., Dawson, L. A., Hong, T. S., Palta, M., Herman, J. M., Evans, D. B., Tsai, S., Ferrone, C. R., Fleming, J. B., Chang, D. T., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01220 · Cited by 33
Lin, J., Zhai, S., Zou, S., Xu, Z., Zhang, J., Jiang, L., Deng, X., Chen, H., Peng, C., Zhang, J., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02097-0 · Cited by 33
“Although several comprehensive clinical trials using gemcitabine-based chemotherapeutics have been conducted on patients with PC, they have shown few benefits [1, 22].”
BackgroundHill, C., Fu, W., Hu, C., Sehgal, S., Reddy, A. V., He, J. P., Herman, J. M., Meyer, J. J., Zaheer, A., & Narang, A. K. (2022) · Practical Radiation Oncology · doi:10.1016/j.prro.2022.01.005 · Cited by 33
Integrin β1 in Pancreatic Cancer: Expressions, Functions, and Clinical Implications
Li, J., Peng, L., Chen, Q., Ye, Z., Zhao, T., Hou, S., Gu, J., & Hang, Q. (2022) · Cancers · doi:10.3390/cancers14143377 · Cited by 39
“Thus far, since no other effective screening techniques or biomarkers other than CA19-9 have been identified for PC, most patients (80–85%) are already in an advanced stage when diagnosed, and the survival rate remains low [171].”
BackgroundThe therapeutic potential of natural products for treating pancreatic cancer
He, X., Wang, N., Zhang, Y., Huang, X., & Wang, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1051952 · Cited by 39
“Immunotherapy includes tumor vaccine, adoptive cell immunotherapy, oncolytic virus therapy, immune checkpoint inhibitors, etc (Conroy et al., 2018).”
BackgroundHenry, A. C., van Dongen, J. C., van Goor, I. W. J. M., Smits, F. J., Nagelhout, A., Besselink, M. G., Busch, O. R., Bonsing, B. A., Bosscha, K. P., van Dam, R. M., et al. (2023) · BJS Open · doi:10.1093/bjsopen/zrac174 · Cited by 40
Cui, J., Jiao, F., Li, Q., Wang, Z., Fu, D., Liang, J., Liang, H., Xia, T., Zhang, T., Zhang, Y., et al. (2022) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2022.08.006 · Cited by 41
“15 , 51–54 It is recommended that adjuvant 1A) 53 2. mFOLFIRINOX (category 1A) 54 3.”
Exarchakou, A., Papacleovoulou, G., Rous, B., Magadi, W., Rachet, B., Neoptolemos, J. P., & Coleman, M. P. (2020) · Pancreatology · doi:10.1016/j.pan.2020.01.012 · Cited by 35
Catenacci, D. V. T., Chase, L. M., Lomnicki, S., Karrison, T. G., Marsh, R., Rampurwala, M. M., Narula, S., Alpert, L., Setia, N., Xiao, S., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.21290 · Cited by 32
Sahni, S., Nahm, C. B., Krisp, C., Molloy, M. P., Mehta, S., Maloney, S., Itchins, M., Pavlakis, N., Clarke, S. J., Chan, D. L. H., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00237 · Cited by 36
He, C., Wang, J., Zhang, Y., Lin, X., & Li, S. (2020) · Pancreatology · doi:10.1016/j.pan.2020.02.009 · Cited by 32
Amrutkar, M., Vethe, N. T., Verbeke, C. S., Aasrum, M., Finstadsveen, A. V., Sántha, P., & Gladhaug, I. P. (2020) · Cancers · doi:10.3390/cancers12123628 · Cited by 42
“Although shown to be less effective than FOLFIRINOX (FOLinic acid, 5-FU, IRINotecan, and OXaliplatin) in the adjuvant setting [6], in metastatic PDAC gemcitabine remains the preferred drug in combination with nab-paclitaxel, or in monotherapy for patients not suitable for aggressive chemotherapy [7,8].”
BackgroundImmunotherapy for pancreatic ductal adenocarcinoma
Carpenter, E. S., Nelson, S., Bednar, F., Cho, C. S., Nathan, H., Sahai, V., di Magliano, M. P., & Frankel, T. L. (2021) · Journal of Surgical Oncology · doi:10.1002/jso.26312 · Cited by 38
The Landmark Series: Preoperative Therapy for Pancreatic Cancer
Patel, S. H., Katz, M. H. G., & Ahmad, S. A. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-10075-1 · Cited by 35
“An important caveat to this trial is the patient population that will likely not be ideal for this regimen are those with poor performance status or are too frail to tolerate an extended course of FOLFIRINOX.”
BackgroundInfluentialZhang, Y., Huang, Z.-X., & Song, B. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i22.3037 · Cited by 32
Dardare, J., Witz, A., Merlin, J., Bochnakian, A., Toussaint, P., Gilson, P., & Harlé, A. (2021) · Pharmaceuticals · doi:10.3390/ph14080740 · Cited by 37
“The FOLFIRINOX protocol (combination of fluorouracil, leucovorin, irinotecan, and oxaliplatin) is now the first-line option in adjuvant settings or for patients with metastatic disease [58,59].”
BackgroundAdjuvant Treatment in Pancreatic Cancer: Shaping the Future of the Curative Setting
Pappalardo, A., Giunta, E. F., Tirino, G., Pompella, L., Federico, P., Daniele, B., Vita, F. D., & Petrillo, A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.695627 · Cited by 35
Challenges and Future Perspectives of Immunotherapy in Pancreatic Cancer
Wandmacher, A. M., Letsch, A., & Sebens, S. (2021) · Cancers · doi:10.3390/cancers13164235 · Cited by 38
Early-onset pancreatic cancer: Clinical characteristics and survival outcomes
Takeda, T., Sasaki, T., Inoue, Y., Okamoto, T., Mori, C., Mie, T., Furukawa, T., Yamada, Y., Kasuga, A., Matsuyama, M., et al. (2022) · Pancreatology · doi:10.1016/j.pan.2022.04.003 · Cited by 41
Cellular metabolism in pancreatic cancer as a tool for prognosis and treatment (Review)
Zuzčák, M., & Trnka, J. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5383 · Cited by 39
Personalized matched targeted therapy in advanced pancreatic cancer: a pilot cohort analysis
Shaya, J. A., Kato, S., Adashek, J. J., Patel, H., Fanta, P. T., Botta, G. P., Sicklick, J. K., & Kurzrock, R. (2023) · npj Genomic Medicine · doi:10.1038/s41525-022-00346-5 · Cited by 33
Bratlie, S. O., Wennerblom, J. H., Vilhav, C., Persson, J., & Rangelova, E. B. (2021) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-2020-slapc-04 · Cited by 31
“Should the patients with clinical but not histologic infiltration be denied resection then? Does “bad” location necessarily translate into “bad” biology? Critical evaluation of the watershed between what is technical challenge and aggressive biology is essential, particularly when potent oncologic treatments are now a…”
BackgroundVernuccio, F., Messina, C. G. M., Merz, V., Cannella, R., & Midiri, M. (2021) · Diagnostics · doi:10.3390/diagnostics11112166 · Cited by 34
Wang, M., Hu, Q., Huang, J., Zhang, F., Yao, Z., Shao, S., Zhao, X., & Liang, T. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202203264 · Cited by 38
IDH1 Inhibition Potentiates Chemotherapy Efficacy in Pancreatic Cancer
Zarei, M., Hajihassani, O., Hue, J. J., Loftus, A. W., Graor, H. J., Nakazzi, F., Naji, P., Boutros, C. S., Uppin, V., Gohar, A. V., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-1895 · Cited by 36
Reni, M., Macchini, M., Orsi, G., Procaccio, L., Malleo, G., Carconi, C., Rapposelli, I. G., Bencardino, K. B., Scartozzi, M., Balzano, G., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01685-x · Cited by 46
Oneda, E., & Zaniboni, A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8111922 · Cited by 32
Exosomes as Pleiotropic Players in Pancreatic Cancer
Lellis, L. D., Florio, R., Bella, M. C. D., Brocco, D., Guidotti, F., Tinari, N., Grassadonia, A., Lattanzio, R., Cama, A., & Veschi, S. (2021) · Biomedicines · doi:10.3390/biomedicines9030275 · Cited by 31
“Moreover, the 3-year recurrence rate exceeds 60% even when the most effective adjuvant chemotherapy regimens, such as mFOLFIRINOX, are used [3].”
Backgroundde Jong, E. J. M., van der Geest, L. G., Besselink, M. G., Bouwense, S. A. W., Buijsen, J., Dejong, C. H. C., Koerkamp, B. G., Heij, L. R., de Hingh, I. H. J. T., Hoge, C. V., et al. (2022) · HPB · doi:10.1016/j.hpb.2022.01.009 · Cited by 31
Wu, W., Miao, Y., Yang, Y., Lou, W., & Zhao, Y. (2021) · Journal of Pancreatology · doi:10.1097/jp9.0000000000000086 · Cited by 31
“It has been well demonstrated that R0 resection and postoperative chemotherapy could prolong the survival of patients with pancreatic cancer.([26,27]) The pancreas is a thin organ without a capsule, and cancer cells could easily invade the surrounding fat tissue.”
Backgroundvan Goor, I. W. J. M., Schouten, T. J., Verburg, D. N., Besselink, M. G., Bonsing, B. A., Bosscha, K. P., Brosens, L. A. A., Busch, O. R., Cirkel, G. A., van Dam, R. M., et al. (2023) · Annals of Surgery · doi:10.1097/sla.0000000000006004 · Cited by 37
“4,25 28 It is reasonable to believe these changes in (neo)adjuvant treatment will also affect 5-year DFS rates, but this remains to be evaluated in future studies.”
BackgroundAdjuvant treatment of pancreatic cancer
Conroy, T., & Ducreux, M. P. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000546 · Cited by 31
Self-citationHypoxia, a Targetable Culprit to Counter Pancreatic Cancer Resistance to Therapy
Khouzam, R. A., Lehn, J., Mayr, H., Clavien, P., Wallace, M. B., Ducreux, M. P., Limani, P., & Chouaïb, S. (2023) · Cancers · doi:10.3390/cancers15041235 · Cited by 39
“This therapeutic regimen leads to superior outcomes in terms of both disease-free survival and overall survival in R0- and R1-resected PDAC [61].”
BackgroundPancreatic ductal adenocarcinoma (PDAC): clinical progress in the last five years
Mosalem, O. M., Abdelhakeem, A. A. F., Abdel-Razeq, N. H., & Babiker, H. M. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2473698 · Cited by 39
Gao, X., Jiang, M., Chu, Y., Han, Y., Jin, Y., Zhang, W., Wang, W., Yang, S., Li, W., Fan, A., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.09.026 · Cited by 35
PRMT5: An Emerging Target for Pancreatic Adenocarcinoma
Lee, M. K. C., Grimmond, S. M., McArthur, G. A., & Sheppard, K. E. (2021) · Cancers · doi:10.3390/cancers13205136 · Cited by 33
“In the best-case scenario, patients newly diagnosed with PDAC undergo both surgical resection and complete six months of modified FOLFIRINOX adjuvant chemotherapy to achieve a median OS of 54 months and 5 year OS of 43% [9,53].”
MethodRozengurt, E., & Eibl, G. (2021) · Cancers · doi:10.3390/cancers13205126 · Cited by 30
“Furthermore, the benefit in prolonging survival by current neo-adjuvant and adjuvant chemotherapeutic regimens is modest and recurrences occur often [3,4].”
BackgroundTang, S., Yu, H., Ding, L., Tang, W., Yu, A., Zhang, C., Sil, D., Xie, Y., & Oupický, D. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00653 · Cited by 31
Nagakawa, Y., Jang, J.-Y., Kawai, M., Kim, S. C., Inoue, Y., Matsuyama, R., Heo, J. S., Honda, M., Sugiura, T., Ohtsuka, M., et al. (2021) · Annals of Surgery · doi:10.1097/sla.0000000000005330 · Cited by 30
Henry, A. C., Schouten, T. J., Daamen, L. A., Walma, M. S., Noordzij, P. G., Cirkel, G. A., Los, M., Besselink, M. G., Busch, O. R., Bonsing, B. A., et al. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-11831-7 · Cited by 33
Liu, K., Geng, Y., Wang, L., Xu, H., Zou, M., Li, Y., Zhao, Z., Chen, T., Xu, F., Sun, L. D., et al. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13279 · Cited by 32
O'Reilly, E. M., & Ferrone, C. R. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03318 · Cited by 30
Comprehensive review of undifferentiated carcinoma of the pancreas: from epidemiology to treatment
Imaoka, H., Ikeda, M., Umemoto, K., Sunakawa, Y., Ueno, M., Ueno, H., Ozaka, M., Kuwahara, T., Okano, N., Kanai, M., et al. (2023) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyad062 · Cited by 29
Liu, R., Li, J., Liu, L., Wang, W., & Jia, J. (2024) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2024.07.004 · Cited by 39
Tao, J., Gu, Y., Zhang, Z., Weng, G., Liu, Y., Ren, J., Shi, Y., Qiu, J., Wang, Y., Su, D., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03201-w · Cited by 32
“Even though the primary tumor is surgically removed, approximately 70% of patients relapse with hepatic metastasis within 2 years [6].”
BackgroundLung recurrence and its therapeutic strategy in patients with pancreatic cancer
Kurahara, H., Maemura, K., Mataki, Y., Tanoue, K., Iino, S., Kawasaki, Y., Idichi, T., Arigami, T., Mori, S., Shinden, Y., et al. (2019) · Pancreatology · doi:10.1016/j.pan.2019.11.015 · Cited by 33
Ishido, K., Hakamada, K., Kimura, N., Miura, T., & Wakiya, T. (2020) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12379 · Cited by 29
Yu, Q., Jobin, C., & Thomas, R. M. (2021) · Neoplasia · doi:10.1016/j.neo.2020.12.008 · Cited by 33
“However, since the introduction f FOLFIRINOX (5-FU, leucovorin, irinotecan, and oxaliplatin) in the djuvant and metastatic setting for PDAC, with both indications having uperior survival outcomes to gemcitabine alone, attention has turned back o combinatorial 5-FU therapy [2 , 7] .”
BackgroundMehtsun, W. T., McCleary, N. J., Maduekwe, U. N., Wolpin, B. M., Schrag, D., & Wang, J. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.5407 · Cited by 31
Racu, M.-L., Lebrun, L., Schiavo, A. A., Campenhout, C. V., Clercq, S. D., Absil, L., Minguijón, E., Maris, C., Decaestecker, C., Salmon, I. J., et al. (2022) · Cancers · doi:10.3390/cancers14040973 · Cited by 36
“The accession of modified FOLFIRINOX as an adjuvant therapy might have modestly increased disease-free survival (DFS) and OS, but at the expense of a greater number of toxic effects [8].”
BackgroundSubtyping for pancreatic cancer precision therapy
Huang, X., Zhang, G., & Liang, T. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.03.005 · Cited by 33
Long Non-Coding RNAs in Pancreatic Cancer: Biologic Functions, Mechanisms, and Clinical Significance
Li, J., Hou, S., Ye, Z., Wang, W., Hu, X., & Hang, Q. (2022) · Cancers · doi:10.3390/cancers14092115 · Cited by 30
“Unfortunately, there is still a lack of credible biomarkers and effective therapeutic strategies for clinical application in PC [5].”
BackgroundSchouten, T. J., Daamen, L. A., Dorland, G. A., van Roessel, S. R., Groot, V. P., Besselink, M. G., Bonsing, B. A., Bosscha, K. P., Brosens, L. A. A., Busch, O. R., et al. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-11664-4 · Cited by 35
Shi, Y.-H., Xu, Q., Zhu, Y., Liu, Z., Zhao, G., Liu, Q., Wang, X.-Y., Wang, J., Xu, X. S., Su, Q., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.11.004 · Cited by 30
“19 However, PDAC resistance to gemcitabine remains one of the greatest challenges in treating the disease.”
BackgroundTomii, A., Higa, M., Naito, K., Kurata, K., Kobayashi, J., Takei, C., Yuasa, K., Koto, Y., & Shimizu, H. (2023) · Bioscience Biotechnology and Biochemistry · doi:10.1093/bbb/zbad055 · Cited by 31
Aslakson, R. A., Chandrashekaran, S., Rickerson, E. M., Fahy, B. N., Johnston, F. M., Miller, J., Conca-Cheng, A. M., Wang, S., Morris, A. M., Lorenz, K., et al. (2019) · Journal of Palliative Medicine · doi:10.1089/jpm.2019.0130 · Cited by 31
Zhou, Y., Zhou, Y., Wang, K., Li, T., Zhang, M., Yang, Y., Wang, R., & Hu, R. (2019) · Cancers · doi:10.3390/cancers11121881 · Cited by 28
Pancreatic exocrine insufficiency following pancreatoduodenectomy: A prospective bi-center study
Kroon, V. J., Daamen, L. A., Tseng, D. S. J., de Vreugd, A. R., Brada, L. J. H., Busch, O. R., Derksen, T. C., Gerritsen, A., Rombouts, S. J. E., Smits, F. J., et al. (2022) · Pancreatology · doi:10.1016/j.pan.2022.08.002 · Cited by 29
Schwarz, L., Bachet, J., Meurisse, A., Bouché, O., Assénat, E., Piessen, G., Hammel, P. R., Régenet, N., Taı̈eb, J., Turrini, O., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-01378 · Cited by 28
Self-citationDucreux, M. P., Desgrippes, R., Rinaldi, Y., Fiore, F. D., Guimbaud, R., Evesque, L., Bachet, J., Vanelslander, P., Lecomte, T., Capitain, O., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-02210 · Cited by 46
Self-citation
Metadata
- Authors
- Conroy, T., Hammel, P., Hebbar, M., Ben Abdelghani, M., Wei, A. C., Raoul, J.-L., Choné, L., Francois, E., Artru, P., Biagi, J. J., Lecomte, T., Assenat, E., Faroux, R., Ychou, M., Volet, J., Sauvanet, A., Breysacher, G., Di Fiore, F., Cripps, C., Kavan, P., Texereau, P., Bouhier-Leporrier, K., Khemissa-Akouz, F., Legoux, J.-L., Juzyna, B., Gourgou, S., O’Callaghan, C. J., Jouffroy-Zeller, C., Rat, P., Malka, D., Castan, F., & Bachet, J.-B.
- Affiliations
- Hôpital Beaujon (FR)
- From the Institut de Cancérologie de Lorraine and Université de Lorraine (T.C.) and Centre Hospitalier Universitaire (L.C.), Nancy, Hôpital Beaujon and University Paris VII, Clichy (P.H., A.S.), Hôpital Huriez, Lille (M.H.), Centre Paul Strauss, Strasbourg (M.B.A.), Institut Paoli-Calmettes, Marseille (J.-L.R.), Centre Antoine-Lacassagne, Nice (E.F.), Hôpital Jean-Mermoz, Lyon (P.A.), Hôpital Trousseau, Tours (T.L.), Centre Hospitalier Universitaire de Saint-Eloi (E.A.) and Institut du Cancer de...
- Université de Montpellier (FR)
- Université Paris-Saclay (FR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-12-20
- Volume
- 379
- Issue
- 25
- Pages
- 2395-2406
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2903623792
- Cited by
- 2,874
- References
- 22
- Citations by year
- 2026: 219 · 2025: 316 · 2024: 337 · 2023: 457 · 2022: 449 · 2021: 512 · 2020: 376 · 2019: 202 · 2018: 1
- FWCI
- 102.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Funders
- Canadian Cancer Society (Program Grant #704970)
- Institut National du Cancer (Clinical Research Hospital Program grant (PHRC11-0)
- 7 Days in May
- French National League against Cancer
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- FOLFIRINOX, gemcitabine, adjuvant chemotherapy, pancreatic ductal adenocarcinoma, resected pancreatic cancer, disease-free survival, overall survival, oxaliplatin, irinotecan, 5-fluorouracil, leucovorin, adverse events, treatment safety, secondary malignancies, metastatic pancreatic cancer, combination chemotherapy
- MeSH terms
- Irinotecan, Oxaliplatin, Gemcitabine, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Leucovorin, Deoxycytidine, Drug Combinations, Female, Fluorouracil, Humans, Male, Middle Aged, Organometallic Compounds, Pancreatic Neoplasms, Prospective Studies, Proportional Hazards Models, Chemotherapy, Adjuvant, Lung Diseases, Interstitial, Disease-Free Survival
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.